Introduction {#s1}
============

The development of resistance to antituberculosis drugs during treatment, known as acquired resistance, can lead to the emergence of resistant strains and consequent poor clinical outcomes [@pone.0083006-Seung1]--[@pone.0083006-Temple1]. Acquired resistance is associated with improper use of antibiotics, inadequate regimens, or incomplete treatment [@pone.0083006-Mitchison1]--[@pone.0083006-World1]. However, it is not known if genetic bacterial strain differences are associated with the likelihood of acquired resistance.

The *Mycobacterium tuberculosis* complex (MTBC) comprises several species, of which *M. tuberculosis*, *M. bovis, and M. africanum* are most commonly associated with tuberculosis in humans. Of these, *M. bovis* is unique in that it is intrinsically resistant to pyrazinamide, one of the first-line drugs used to treat tuberculosis [@pone.0083006-deJong1]. Four main phylogenetic lineages of *M. tuberculosis* (Indo-Oceanic, East Asian, East African-Indian, and Euro-American) and two lineages of *M. africanum* (West African 1 and 2) have been identified [@pone.0083006-Gagneux1]. Studies from a variety of settings have reported associations between East Asian lineage or its dominant member, the Beijing genotype, and drug resistance [@pone.0083006-Glynn1]--[@pone.0083006-Fenner1]. However, these epidemiologic studies have not looked specifically at acquired resistance documented by repeated drug susceptibility testing during the course of tuberculosis treatment. Thus, these associations may reflect an increased risk of being infected with a strain that is already drug-resistant rather than an increased risk of developing resistance during treatment.

Because of the clinical and public health implications of developing resistance during treatment, we sought to determine whether MTBC species or lineage was associated with acquired resistance to four major classes of antituberculosis drugs using data from the U.S. National Tuberculosis Surveillance System (NTSS) and National Tuberculosis Genotyping Service (NTGS).

Methods {#s2}
=======

Case Inclusion {#s2a}
--------------

We analyzed NTSS data for new (i.e., occurring in a patient without prior history of tuberculosis) tuberculosis cases with baseline positive cultures from the 50 states and the District of Columbia during 2004--2011 for which a species or lineage was assigned, and for which drug susceptibility test (DST) results were available. NTSS collects sociodemographic and clinical information, including DST results, on all tuberculosis cases in the United States. DSTs for first-line drugs on the initial positive culture are routine in the United States, but repeated DSTs and DSTs on second-line drugs are performed only when indicated. DST results for the first isolate tested (i.e., initial DST results) are reported to NTSS; if repeated DST is performed, results for the last isolate on which DST was performed (i.e., final DST results) are reported to NTSS. Since 2004, NTGS has routinely performed genotyping on culture-positive cases and assigned lineage based on spoligotype and 12-locus mycobacterial interspersed repetitive unit variable number of tandem repeat [@pone.0083006-Click1]. The rules used for classification of lineage have been shown produce results consistent with lineage assignment based on long-sequence polymorphisms [@pone.0083006-Click1]--[@pone.0083006-Gagneux2]. Data from NTGS and NTSS were linked to identify cases with assigned lineage.

We analyzed cases with and without acquired resistance to isoniazid, rifamycins (rifampin, rifabutin, and rifapentine), second-line injectables (amikacin, kanamycin, and capreomycin, referred to collectively from here as "injectables"), and fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, and drugs classified as "other quinolone" in NTSS). For each drug class, we restricted analysis to cases with initial susceptibility to all tested members of the class and a final DST result for at least one member. Acquired resistance to a drug was defined as resistance at the final DST to a drug to which the case's first isolate had been susceptible at the initial DST. Acquired resistance to a drug class was defined as acquired resistance to any of the drugs in the class. No acquired resistance to a drug was defined as susceptibility to that drug at both initial and final DST. No acquired resistance to a drug class was defined as susceptibility at both initial and final DST to at least one member of the class, and susceptibility at final DST to all tested members of the class.

Statistical Analysis {#s2b}
--------------------

We determined characteristics associated with acquired resistance to isoniazid, rifamycins, injectables, and fluoroquinolones by calculating prevalence ratios (PR) with 95% confidence intervals (CI). A 95% CI excluding the null value (i.e., PR = 1.0) was considered statistically significant. We used multivariable Poisson regression to assess factors independently associated with acquired resistance to isoniazid and rifamycins. The initial multivariable model included species and lineage as well as variables with *P*\<0.10 in univariate analysis and potential confounders based on biological plausibility or known epidemiologic association. We assessed confounding in the initial model and used backward elimination to determine variables included in the final model to obtain better precision around point estimates. To test the robustness of the multivariable model, we carried out sensitivity analyses using subsets of included cases. In one analysis, we included only cases caused by *M. tuberculosis* (i.e., excluding those caused by *M. bovis* and *M. africanum*); in another, we included only cases with initial susceptibility to isoniazid, rifampin, and ethambutol. We did not perform multivariable analysis for injectables and fluoroquinolones because of the small number of cases with documented acquired resistance to these drug classes. All statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).

Ethics Statement and Public Availability of Data {#s2c}
------------------------------------------------

All data were collected and analyzed as part of routine public health surveillance. The project was therefore determined not to be human subjects research by the U.S. Centers for Disease Control and Prevention (CDC) and did not require approval by an institutional review board.

Researchers may apply to analyze NTSS and NTGS data at CDC headquarters according to established procedures. In addition, a publicly available version of NTSS data is available at <https://wonder.cdc.gov/tb.html>.

Results {#s3}
=======

Among 105,400 tuberculosis cases counted by NTSS during 2004--2011, 51,223 (48.6%) met our inclusion criteria ([Figure 1](#pone-0083006-g001){ref-type="fig"}). Among this subset of cases, initial DST for isoniazid and at least one rifamycin were almost universal (\>99%). In contrast, 6,258 (12.2%) and 4,742 (9.3%) had an initial DST result for at least one injectable or fluoroquinolone, respectively. For all four drug classes, the majority of cases (\>90%) with initial DST results showed susceptibility at initial DST. For all four drug classes, approximately 8% of cases initially susceptible to the drug class had a final DST result. Out of cases with final DST results, the proportion of cases with acquired resistance ranged from 1.2% for rifamycins to 2.5% for fluoroquinolones.

![Selection of cases included in analysis.\
Abbreviations: TB = tuberculosis, DST = drug susceptibility test, AR = acquired resistance.](pone.0083006.g001){#pone-0083006-g001}

Species and phylogenetic lineage was associated with acquired resistance to isoniazid, rifamycins, injectables, and fluoroquinolones ([Table 1](#pone-0083006-t001){ref-type="table"}). Because the numbers of cases with final DST results for injectables and fluoroquinolones was small, we calculated only crude PRs for these drug classes. *M. bovis* was associated with acquired resistance to both isoniazid (adjusted prevalence ratio \[aPR\] = 8.46, 95% CI 2.96--24.14) and rifamycins (aPR = 4.53, 95% CI 1.29--15.90). East Asian lineage was associated with acquired resistance to fluoroquinolones (PR = 6.10, 95% CI 1.56--23.83).

10.1371/journal.pone.0083006.t001

###### Associations between *M. tuberculosis* complex lineage and acquired resistance to isoniazid, rifamycins, second-line injectables, and fluoroquinolones.

![](pone.0083006.t001){#pone-0083006-t001-1}

                                           Acquired resistance to isoniazid   Acquired resistance to rifamycins   Acquired resistance to injectables   Acquired resistance to fluoroquinolones                       
  --------------------------------------- ---------------------------------- ----------------------------------- ------------------------------------ ----------------------------------------- -------------------- ------------------------
  *M. africanum*                                          --                                 --                                   --                                     --                              --                     --
  *M. bovis*                                    **7.03 (2.66--18.56)**             **8.46 (2.96--24.14)**               **6.61 (2.12--20.65)**                 **4.53 (1.29--15.90)**                    --                     --
  *M. tuberculosis,* EastAfrican-Indian           0.46 (0.06--3.33)                   0.48 (0.07--3.49)                   0.56 (0.08--4.05)                       1.09 (0.14--8.19)              3.64 (0.42--31.27)             --
  *M. tuberculosis,* East Asian                   1.06 (0.52--2.15)                   1.10 (0.45--2.90)                   1.31 (0.63--2.72)                       1.84 (0.86--3.93)              2.59 (0.59--11.38)   **6.10 (1.56--23.83)**
  *M. tuberculosis,* Euro-American                    Reference                           Reference                           Reference                               Reference                      Reference              Reference
  *M. tuberculosis,* Indo-Oceanic                 1.02 (0.41--2.56)                   1.14 (0.45--2.90)                   0.94 (0.34--2.65)                       1.46 (0.49--4.31)                      --                     --

Adjusted for HIV status.

Adjusted for homelessness, HIV status, initial resistance to isoniazid, site of disease, and administration of therapy.

Abbreviations: CI = confidence interval, -- = no prevalence ratio calculated because no cases had acquired resistance.

Sociodemographic and clinical factors showed no statistically significant associations with acquired resistance to isoniazid ([Table 2](#pone-0083006-t002){ref-type="table"}). In contrast, acquired resistance to rifamycins was associated with older age groups (45--64 and ≥65 years), homelessness, injecting drug use, HIV infection, initial resistance to isoniazid, initial resistance to ethambutol, combined pulmonary and extrapulmonary site of disease (including miliary tuberculosis), and self-administered therapy ([Table 3](#pone-0083006-t003){ref-type="table"}).

10.1371/journal.pone.0083006.t002

###### Sociodemographic and clinical factors associated with acquired resistance to isoniazid (N = 3,696).

![](pone.0083006.t002){#pone-0083006-t002-2}

                                                                                               Included cases   Acquired resistancen (% of included)   Crude PR (95% CI)              
  -------------------------------------------------- ---------------------------------------- ---------------- -------------------------------------- ------------------- ----------- -------------------
  Species, lineage                                                *M. africanum*                     16                          0                           (0.0)            --      
                                                           *M. bovis* *M. tuberculosis*              36                          4                          (11.1)         **7.03**    **(2.66--18.56)**
                                                      *M. tuberculosis*, East African-Indian        137                          1                           (0.7)           0.46        (0.06--3.33)
                                                          *M. tuberculosis*, East Asian             541                          9                           (1.7)           1.05        (0.52--2.15)
                                                         *M. tuberculosis*, Euro-American          2,656                         42                          (1.6)         Reference  
                                                         *M. tuberculosis*, Indo-Oceanic            310                          5                           (1.6)           1.02        (0.41--2.56)
  Sex                                                                 Female                       1,068                         23                          (1.7)           1.03        (0.60--1.78)
                                                                       Male                        2,628                         51                          (1.6)         Reference  
  Age                                                                 0--24                         363                          6                           (1.4)           0.80        (0.31--2.11)
                                                                      25--44                       1,284                         28                          (1.7)         Reference  
                                                                      45--64                       1,407                         30                          (1.9)           1.12        (0.64--1.96)
                                                                       ≥65                          642                          10                          (1.1)           0.64        (0.27--1.48)
  Race and ethnicity                                                 Hispanic                      1,123                         24                          (1.9)           1.18        (0.59--2.34)
                                                                 American Indian                     28                          1                           (3.6)           2.25        (0.30--16.58)
                                                                      Asian                         643                          9                           (1.2)           0.78        (0.33--1.88)
                                                                Non-Hispanic Black                 1,063                         18                          (1.7)           1.07        (0.53--2.34)
                                                                Non-Hispanic White                  818                          13                          (1.6)         Reference  
  Country of birth                                                 Foreign-born                    1,864                         32                          (1.7)           0.91        (0.58--1.42)
                                                                    U.S.-born                      1,829                         29                          (1.6)         Reference  
  Region of birth[\*](#nt104){ref-type="table-fn"}                    Africa                        188                          1                           (0.5)           0.34        (0.05--2.45)
                                                       Americas (other than United States)          919                          20                          (2.2)           1.37        (0.78--2.41)
                                                              Eastern Mediterranean                  51                          1                           (2.0)           1.24        (0.17--8.90)
                                                                      Europe                         74                          2                           (2.7)           1.70        (0.41--7.01)
                                                                 South-East Asia                    169                          2                           (1.2)           0.75        (0.18--3.10)
                                                                 Western Pacific                    458                          6                           (1.3)           0.83        (0.35--1.98)
                                                                  United States                    1,829                         29                          (1.6)         Reference  
  In correctional facility at diagnosis                                Yes                          133                          2                           (1.5)           0.91        (0.22--3.67)
                                                                        No                         3,559                         59                          (1.7)         Reference  
  Homeless                                                             Yes                          353                          2                           (0.6)           0.32        (0.08--1.30)
                                                                        No                         3,328                         59                          (1.8)         Reference  
  Injecting drug use                                                   Yes                           97                          2                           (2.1)           1.25        (0.31--5.04)
                                                                        No                         3,572                         59                          (1.7)         Reference  
  Non-injecting drug use                                               Yes                          430                          8                           (1.9)           1.14        (0.44--1.90)
                                                                        No                         3,235                         53                          (1.6)         Reference  
  Excess alcohol use                                                   Yes                          870                          10                          (1.1)           0.73        (0.54--2.37)
                                                                        No                         2,804                         51                          (1.8)         Reference  
  HIV status                                                         Positive                       257                          4                           (1.6)           0.81        (0.29--2.23)
                                                                     Negative                      2,497                         48                          (1.9)         Reference  
                                                                     Unknown                        942                          9                           (1.0)           0.50        (0.24--1.01)
  Initial DST result for rifamycins                              Resistant to any                    20                          1                           (5.0)           3.06        (0.45--21.01)
                                                            Susceptible to all tested              3,672                         60                          (1.6)         Reference  
  Initial DST result for pyrazinamide                               Resistant                        68                          2                           (2.9)           1.98        (0.49--8.01)
                                                                   Susceptible                     2,619                         39                          (1.5)         Reference  
  Initial DST result for ethambutol                                 Resistant                        8                           0                           (0.0)            --      
                                                                   Susceptible                     3,681                         60                          (1.6)         Reference  
  Initial chest radiograph                                           Abnormal                      3,440                         55                          (1.6)           0.78        (0.29--2.14)
                                                                      Normal                        196                          4                           (2.0)         Reference  
  Cavity seen on chest radiograph                                      Yes                         1,598                         27                          (1.7)           1.07        (0.64--1.79)
                                                                        No                         1,972                         31                          (1.6)         Reference  
  Sputum microscopy result for AFB                                   Positive                      2,764                         44                          (1.6)           0.83        (0.46--1.48)
                                                                     Negative                       778                          15                          (1.9)         Reference  
  Site of disease                                              Extrapulmonary only                  179                          1                           (0.6)           0.35        (0.05--2.53)
                                                           Pulmonary and extrapulmonary             364                          10                          (2.7)           1.73        (0.89--3.39)
                                                                  Pulmonary only                   3,152                         50                          (1.6)         Reference  
  Administration of therapy                                          DOT only                      2,232                         38                          (1.7)         Reference  
                                                            Self-administered and DOT              1,216                         18                          (1.5)           0.87        (0.50--1.52)
                                                              Self-administered only                199                          1                           (0.5)           0.30        (0.04--2.14)

Regions defined by World Health Organization [@pone.0083006-World3].

Missing values not reported in table.

Abbreviations: PR = prevalence ratio, CI = confidence interval, DST = drug susceptibility test, AFB = acid-fast bacilli, DOT = directly observed therapy.

10.1371/journal.pone.0083006.t003

###### Sociodemographic and clinical factors associated with acquired resistance to rifamycins (N = 4,005).

![](pone.0083006.t003){#pone-0083006-t003-3}

                                                                                               Included cases   Acquired resistancen (% of included)   Crude PR (95% CI)              
  -------------------------------------------------- ---------------------------------------- ---------------- -------------------------------------- ------------------- ----------- -------------------
  Species, lineage                                                *M. africanum*                     19                          0                           (0.0)            --      
                                                                    *M. bovis*                       39                          3                           (7.7)         **6.61**    **(2.12--20.65)**
                                                      *M. tuberculosis,* East African-Indian        154                          1                           (0.6)           0.56        (0.08--4.05)
                                                          *M. tuberculosis,* East Asian             590                          9                           (1.5)           1.31        (0.63--2.72)
                                                         *M. tuberculosis,* Euro-American          2,836                         33                          (1.2)         Reference  
                                                         *M. tuberculosis,* Indo-Oceanic            364                          4                           (1.1)           0.94        (0.34--2.65)
  Sex                                                                 Female                       1,161                         13                          (1.1)           0.86        (0.46--1.61)
                                                                       Male                        2,841                         37                          (1.3)         Reference  
  Age                                                                 0--24                         399                          3                           (0.8)           0.35        (0.11--1.14)
                                                                      25--44                       1,399                         30                          (2.2)         Reference  
                                                                      45--64                       1,531                         15                          (1.0)         **0.46**    **(0.25--0.85)**
                                                                       ≥65                          673                          2                           (0.3)         **0.14**    **(0.03--0.58)**
  Race and ethnicity                                                 Hispanic                      1,222                         17                          (1.4)           1.72        (0.72--4.12)
                                                                 American Indian                     30                          0                           (0.0)            --      
                                                                      Asian                         748                          8                           (1.1)           1.32        (0.48--3.62)
                                                                Non-Hispanic Black                 1,113                         18                          (1.6)           2.00        (0.84--4.76)
                                                                Non-Hispanic White                  864                          7                           (0.8)         Reference  
  Country of birth                                                 Foreign-born                    2,067                         24                          (1.2)           0.86        (0.50--1.50)
                                                                    U.S.-born                      1,932                         26                          (1.3)         Reference  
  Region of birth[\*](#nt107){ref-type="table-fn"}                    Africa                        204                          3                           (1.5)           1.09        (0.33--3.58)
                                                       Americas (other than United States)          993                          12                          (1.2)           0.90        (0.46--1.77)
                                                              Eastern Mediterranean                  58                          1                           (1.7)           1.28        (0.18--9.28)
                                                                      Europe                         78                          0                           (0.0)            --      
                                                                 South-East Asia                    191                          2                           (1.0)           0.78        (0.19--3.25)
                                                                 Western Pacific                    538                          6                           (1.1)           0.83        (0.34--2.00)
                                                                  United States                    1,932                         26                          (1.3)         Reference  
  In correctional facility at diagnosis                                Yes                          150                          4                           (2.7)           2.23        (0.81--6.11)
                                                                        No                         3,847                         39                          (1.2)         Reference  
  Homeless                                                             Yes                          372                          11                          (3.0)         **2.74**    **(1.42--5.30)**
                                                                        No                         3,613                         39                          (1.1)         Reference  
  Injecting drug use                                                   Yes                          105                          5                           (4.8)         **4.09**    **(1.66--10.10)**
                                                                        No                         3,867                         45                          (1.2)         Reference  
  Non-injecting drug use                                               Yes                          460                          7                           (1.5)           1.24        (0.56--2.74)
                                                                        No                         3,508                         43                          (1.2)         Reference  
  Excess alcohol use                                                   Yes                          933                          14                          (1.5)           1.27        (0.69--2.34)
                                                                        No                         3,045                         36                          (1.2)         Reference  
  HIV status                                                         Positive                       275                          24                          (8.7)         **12.46**   **(6.91--22.45)**
                                                                     Negative                      2,712                         19                          (0.7)         Reference  
                                                                     Unknown                       1,015                         7                           (0.7)           0.98        (0.42--2.23)
  Initial DST result for isoniazid                                  Resistant                       328                          20                          (6.1)         **7.45**    **(4.28--12.98)**
                                                                   Susceptible                     3,667                         30                          (0.8)         Reference  
  Initial DST result for pyrazinamide                               Resistant                        84                          2                           (2.4)           1.76        (0.43--7.16)
                                                                   Susceptible                     2,878                         39                          (1.4)         Reference  
  Initial DST result for ethambutol                                 Resistant                        39                          2                           (5.1)         **4.22**    **(1.06--16.76)**
                                                                   Susceptible                     3,952                         48                          (1.2)         Reference  
  Initial chest radiograph                                           Abnormal                      3,715                         46                          (1.2)           0.69        (0.25--1.91)
                                                                      Normal                        224                          4                           (1.8)         Reference  
  Cavity seen on chest radiograph                                      Yes                         1,731                         16                          (0.9)           0.58        (0.32--1.05)
                                                                        No                         2,136                         34                          (1.6)         Reference  
  Sputum microscopy result for AFB                                   Positive                      2,976                         40                          (1.3)           1.15        (0.58--2.29)
                                                                     Negative                       854                          10                          (1.2)         Reference  
  Site of disease                                              Extrapulmonary only                  203                          1                           (0.5)           0.53        (0.07--3.82)
                                                           Pulmonary and extrapulmonary             386                          17                          (4.4)         **4.70**    **(2.63--8.38)**
                                                                  Pulmonary only                   3,412                         32                          (0.9)         Reference  
  Administration of therapy                                            DOT                         2,418                         29                          (1.2)         Reference  
                                                            Self-administered and DOT              1,322                         13                          (1.0)           0.82        (0.43--1.57)
                                                              Self-administered only                210                          6                           (2.9)         **2.38**    **(1.00--5.67)**

Regions defined by World Health Organization [@pone.0083006-World3].

Missing values not reported in table.

Abbreviations: PR = prevalence ratio, CI = confidence interval, DST = drug susceptibility test, AFB = acid-fast bacilli, DOT = directly observed therapy.

In multivariable analysis, acquired resistance to isoniazid was independently associated with *M. bovis* and with unknown HIV status (aPR = 0.46, 95% CI 0.23--0.95) ([Table 4](#pone-0083006-t004){ref-type="table"}). Acquired resistance to rifamycins was associated with *M. bovis*, homelessness (aPR = 2.21, 95% CI 1.08--4.52), HIV infection (aPR = 8.89, 95% CI 4.43--17.85), initial resistance to isoniazid (aPR = 10.37, 95% CI 5.65--19.00), extrapulmonary site of disease (aPR = 2.31, 95% CI 1.17--4.58), and self-administered therapy (aPR = 2.52, 95% CI 1.01--6.30) ([Table 4](#pone-0083006-t004){ref-type="table"}).

10.1371/journal.pone.0083006.t004

###### Independent predictors of acquired resistance to isoniazid and rifamycins in multivariable regression analysis.

![](pone.0083006.t004){#pone-0083006-t004-4}

                                                                               Adjusted prevalence ratio for acquired resistance to isoniazid (95% CI)   Adjusted prevalence ratio for acquired resistance to rifamycins (95% CI)                      
  ---------------------------------- ---------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------- -------------------
  Species, lineage                                  *M. bovis*                                                **8.46**                                                              **(2.96--24.14)**                                   **4.53**        **(1.29--15.90)**
                                      *M. tuberculosis*, East African Indian                                    0.48                                                                   (0.07--3.49)                                       1.09            (0.14--8.19)
                                          *M. tuberculosis*, East Asian                                         1.10                                                                   (0.53--2.25)                                       1.84            (0.86--3.93)
                                         *M. tuberculosis*, Euro American                                     Reference                                                                                                                 Reference      
                                         *M. tuberculosis*, Indo Oceanic                                        1.14                                                                   (0.45--2.90)                                       1.46            (0.49--4.31)
  Homeless                                             Yes                                              Not included in model                                                            **2.21**                                   **(1.08--4.52)**   
                                                        No                                                                                                                                                                              Reference      
  HIV status                                         Positive                                                   0.67                                                                   (0.24--1.89)                                     **8.89**        **(4.43--17.85)**
                                                     Negative                                                 Reference                                                                                                                 Reference      
                                                     Unknown                                                  **0.46**                                                               **(0.23--0.95)**                                     0.75            (0.29--1.94)
  Initial DST result for isoniazid                  Resistant                                           Not included in model                                                           **10.37**                                   **(5.65--19.00)**  
                                                   Susceptible                                                                                                                                                                          Reference      
  Site of disease                              Extrapulmonary only                                      Not included in model                                                            **2.31**                                   **(1.17--4.58)**   
                                           Pulmonary and extrapulmonary                                                                                                                                                                   0.44            (0.06--3.28)
                                                  Pulmonary only                                                                                                                                                                        Reference      
  Administration of therapy                          DOT only                                           Not included in model                                                           Reference                                                      
                                            Self-administered and DOT                                                                                                                                                                     0.84            (0.44--1.63)
                                              Self-administered only                                                                                                                                                                    **2.52**        **(1.01--6.30)**

Abbreviation: CI = confidence interval, DST = drug susceptibility test, DOT = directly observed therapy.

We repeated univariate and multivariable analyses restricting cases to those caused by *M. tuberculosis* (data not shown). Similar associations with independent predictors other than *M. bovis* were observed for both acquired resistance to isoniazid and acquired resistance to rifamycins.

We also repeated univariate and multivariable analyses restricting cases to those with documented initial susceptibility to isoniazid, rifampin, and ethambutol (data not shown). Analysis of predictors associated with acquired resistance to isoniazid gave similar results. The association between *M. bovis* and acquired resistance to rifamycins lost statistical significance (aPR = 3.83, 95% CI 0.99--14.79), but independent associations with homelessness, HIV infection, and extrapulmonary site of disease were once again observed. We did not repeat analyses restricting cases to those with documented initial susceptibility to pyrazinamide because almost all *M. bovis* cases would have been excluded from analysis, as well as a substantial portion of other cases that lacked pyrazinamide DST results.

Discussion {#s4}
==========

This large study among tuberculosis cases with repeated DST results suggests an association between species and lineage of MTBC bacteria and acquired resistance to antituberculosis drugs. We found *M. bovis* to be associated with acquired resistance to both isoniazid and rifamycins, and these associations were independent of other predictors of acquired resistance such as initial resistance to another first-line drug and HIV infection. In addition, our results suggest an association between East Asian lineage and acquired resistance to fluoroquinolones, although the number of cases analyzed was too small to support multivariable analysis to identify potential confounders.

The association between *M. bovis* and acquired resistance to both isoniazid and rifamycins may be partly attributable to its inherent resistance to pyrazinamide, a drug included in standard four-drug regimens used to treat drug-susceptible tuberculosis [@pone.0083006-CDC1] because of its sterilizing properties and its ability to kill dormant, non-replicating bacilli [@pone.0083006-Mitchison2], [@pone.0083006-Zhang1]. However, our results suggest that resistance to pyrazinamide may not entirely explain the association between *M. bovis* and acquired resistance, as initial resistance to pyrazinamide did not predict acquired resistance to isoniazid or rifampin in our analysis. Issues with false positivity associated with standard methods for testing pyrazinamide susceptibility [@pone.0083006-Zhang2], [@pone.0083006-Chedore1] may have contributed to this lack of an association. However, only about half of the cases included in our analyses that had initial resistance to pyrazinamide were caused by *M. bovis*, and when *M. bovis* cases were excluded from analysis, no association was observed between resistance to pyrazinamide at initial DST and acquired resistance to either isoniazid or rifamycins. These results suggest that *M. bovis* may have attributes other than resistance to pyrazinamide that increase the likelihood of its acquiring resistance to other drugs.

The finding that East Asian lineage is associated with acquired resistance to fluoroquinolones is consistent with the numerous studies reporting associations between East Asian lineage or the Beijing genotype with drug resistance [@pone.0083006-Glynn1]--[@pone.0083006-Fenner1]. Furthermore, an association between the Beijing genotype and primary fluoroquinolone resistance has been reported [@pone.0083006-Duong1]. A potential biological mechanism that could explain associations between this lineage and both initial and acquired drug resistance has been suggested by *in vitro* studies reporting that East Asian strains have an elevated basal mutation rate compared to East African-Indian and Euro-American strains [@pone.0083006-deSteenwinkel1], [@pone.0083006-Ford1], and are therefore more likely to develop mutations leading to drug resistance. Finally, our observation that acquired resistance to fluoroquinolones was associated with East Asian lineage but not to region of origin suggests that the observed association is not attributable to host factors among persons from regions where the East Asian lineage is common [@pone.0083006-Gagneux1].

Our observation that initial resistance to isoniazid is associated with acquired resistance to rifamycins is consistent with other studies that have shown initial resistance to one or more drugs to be a strong risk factor for additional acquired resistance [@pone.0083006-Lew1]. Surprisingly, we did not observe strong evidence for an association between initial resistance to rifamycins and acquired resistance to isoniazid. The lack of association could be attributable to the small number of cases with initial rifamycin resistance in the absence of initial isoniazid resistance. Out of 3,692 cases with initial susceptibility to isoniazid and a documented initial DST result for at least one rifamycin, only 20 (0.5%) were resistant to rifamycins. In contrast, 328 (8.2%) of the 3,995 cases with initial susceptibility to rifamycins and a documented initial DST result for isoniazid were resistant to isoniazid.

The association between HIV infection and acquired resistance to rifamycins may be attributable to interactions between rifamycins and antiretroviral drugs used to treat HIV [@pone.0083006-Lee1], and is consistent with previous studies that observed acquired resistance to both rifampin and rifapentine in patients being treated for TB-HIV [@pone.0083006-Vernon1], [@pone.0083006-Li1]. However, we could not test this hypothesis as NTSS does not collect information on antiretroviral therapy. The basis of the negative association between unknown HIV status and acquired resistance to isoniazid is unknown, but may reflect an association not with HIV status but with particular tuberculosis control programs that did not report HIV status of patients during the time period of this analysis [@pone.0083006-CDC2].

Finally, we observed an independent association between self-administered therapy and acquired resistance to rifamycins, reinforcing the rationale behind using directly observed therapy (DOT) to promote completion of treatment and discourage acquisition of drug resistance [@pone.0083006-CDC1], [@pone.0083006-World2]. This contrasts with results of a recent meta-analysis of prospective observational studies and controlled trials, which found no statistically significant pooled risk difference for DOT versus self-administered therapy based on two included studies reporting acquired drug resistance as an outcome [@pone.0083006-Pasipanodya1]. In their discussion, the authors suggest that retrospective studies reporting an association between poor treatment outcomes and self-administered therapy as compared to DOT have typically been unable to distinguish between the effect of direct observation itself and that of the programmatic improvements that accompanied the establishment of DOT as the standard of care. We believe our findings do not reflect this limitation because the current U.S. national TB elimination strategy, including DOT, was implemented during the 1990s, and important programmatic improvements are not likely to have been major factors during 2004--2011.

Our study was subject to several important limitations. First, initial DST for first-line drugs is routine, but repeated DST is discretionary in the United States. Therefore, the cases included in our analysis represented a small proportion of genotyped tuberculosis cases in NTSS, and are not representative of the general tuberculosis patient population in the United States. Because clinicians are more likely to repeat DSTs for patients because of clinical indications such as apparently ineffective treatment, the prevalence of acquired resistance among cases included in our analysis likely overestimates the prevalence in the general tuberculosis patient population. Furthermore, because DST for second-line drugs is also discretionary, very few genotyped cases had both initial and final DST results for injectables and fluoroquinolones. The small number of cases with acquired resistance to these two drug classes prevented us from analyzing the association between acquired resistance and *M. bovis*, and may have contributed to the lack of an observed association between lineage and acquired resistance to injectables. In addition, because of the small number of cases, we were unable to perform multivariable analyses, although clinical and sociodemographic factors associated with acquired resistance to both injectables and fluoroquinolones have previously been reported [@pone.0083006-Ershova1]. Finally, the small number of cases with acquired resistance to any drug makes overinterpretation of results possible.

Our study was also limited by the data available through NTSS and NTGS. Because only DST results for the first and last isolate tested are reported to NTSS, we could not include time to acquisition of drug resistance in our analysis. In addition, we could not include treatment regimen in our analysis because only the drugs in the initial regimen are reported to NTSS. Finally, while drug availability in individual patients may influence risk of acquired resistance [@pone.0083006-Pasipanodya2], no data on serum drug concentrations or other pharmacokinetic measurements were available in NTSS that would enable us to consider this factor in our analysis.

Based on the data available in NTGS, we did not have genotyping results for both initial and final isolates and therefore could not confirm that the same strain was tested at initial and final DSTs. It is therefore possible that some cases were misclassified as having acquired resistance when in fact the change in DST result was attributable to a mixed-strain infection or re-infection during treatment, although the risk for either is generally thought to be low in low-incidence settings such as the United States [@pone.0083006-Cohen1], [@pone.0083006-Jasmer1]. In addition, although NTGS has been performing routine genotyping on culture-positive cases since 2004, not all states started utilizing the service comprehensively at the same time, and the proportion of culture-positive cases with available genotypes ranged from 52% in 2004 to 89% in 2010. Because some states selectively genotyped cases in earlier years, cases with certain characteristics, such as being associated with outbreaks, may be overrepresented in our sample.

In conclusion, among patients reported in the U.S. surveillance system with both initial and final DST results, *M. bovis* was independently associated with acquired resistance to isoniazid and rifamycins, and East Asian lineage may be associated with acquired resistance to fluoroquinolones. These results suggest that knowledge of risk factors for *M. bovis* infection such as Hispanic ethnicity, age \<15 years, and extrapulmonary disease [@pone.0083006-Hlavsa1] may be useful for identifying patients with increased risk for acquired isoniazid and rifamycin resistance. In addition, patients from countries in East and Southeast Asia, where the East Asian lineage is common, may be at increased risk for acquired resistance to fluoroquinolones [@pone.0083006-Gagneux1]. However, given the limitations of U.S. surveillance data, prospective clinical studies are needed to confirm the clinical significance of these findings, including whether rapid genotyping of isolates at the outset of treatment may benefit patient management.
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